Galmed (GLMD) CFO details Ordinary Share, option and RSU holdings

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. filed a Form 3 showing Chief Financial Officer Doron Leib Cohen’s existing equity holdings in the company. He directly holds 22,083 Ordinary Shares, several blocks of Restricted Share Units, and options to purchase 208 Ordinary Shares at an exercise price of 68.4000 per share expiring on February 23, 2032.

One RSU grant of 2,083 units vests on August 7, 2026, another of 23,333 units vests in four equal parts on May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, and a further RSU award of 25,000 units vests one-third on August 26, 2026 with the rest in four installments through August 26, 2028, all subject to his continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cohen Doron Leib

(Last) (First) (Middle)

C/O MEITAR LAW OFFICES

16 ABBA HILLEL SILVER RD.

(Street)

RAMAT GAN 5250608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Galmed Pharmaceuticals Ltd. [ GLMD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	22,083	D
Restricted Share Units	2,083(1)	D
Restricted Share Units	23,333(2)	D
Restricted Share Units	25,000(3)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares	02/23/2022	02/23/2032	Ordinary Shares	208	$68.4	D

Explanation of Responses:

1. These restricted share units vest on August 7, 2026, subject to the Reporting Person's continued service.

2. These restricted share units vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service.

3. These restricted share units vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.

	/s/ Doron Cohen	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Galmed Pharmaceuticals (GLMD) Form 3 filing show for the CFO?

The Form 3 shows CFO Doron Leib Cohen’s existing equity stake in Galmed. It lists 22,083 Ordinary Shares, several Restricted Share Unit grants, and options for 208 Ordinary Shares at an exercise price of 68.4000, all held directly.

How many Galmed (GLMD) Ordinary Shares does the CFO hold directly?

The CFO directly holds 22,083 Ordinary Shares of Galmed Pharmaceuticals Ltd. This figure comes from the reported total shares following the transaction line for Ordinary Shares, reflecting his direct ownership position at the time of the Form 3 filing.

What option position does the Galmed (GLMD) CFO report on Form 3?

He reports options to purchase Ordinary Shares with an exercise price of 68.4000 per share. These options cover 208 underlying Ordinary Shares and have an expiration date of February 23, 2032, providing long-dated potential equity exposure if exercised.

When do the Galmed (GLMD) CFO’s RSU awards disclosed on Form 3 vest?

One RSU grant vests on August 7, 2026. Another vests in four equal installments on May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027. A third award vests from August 26, 2026 through August 26, 2028, all conditioned on continued service.

What are the sizes of the RSU holdings reported by the Galmed (GLMD) CFO?

The Form 3 lists Restricted Share Unit positions of 2,083 units, 23,333 units, and 25,000 units. Each block is tied to specific vesting schedules between 2026 and 2028, and all vesting is subject to the CFO’s continued service with Galmed.

What is the purpose of this Galmed (GLMD) Form 3 for the CFO?

This Form 3 serves as the initial statement of beneficial ownership for the CFO. It discloses his existing Ordinary Share holdings, outstanding option award, and unvested Restricted Share Units, providing the market with a baseline view of his equity interests.